Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are given in the enclosed document. Strong product mix, new launches to keep Sanofi India margins elevated
Street positive given attractive valuations; stock trading at 16x its CY20 estimates Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Notice to shareholders of the Company published today, in newspapers, Business Standard and Sakal. Sanofi India Ltd - 500674 - Fixes Book Closure for Final Dividend & AGM
Sanofi India Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from April 30, 2019 to May 07, 2019 (both days inclusive) for the purpose of Payment of Final Dividend & Annual General Meeting (AGM) of the Company to be held on May 07, 2019.The final dividend, if approved by the shareholders shall be payable on or after May 14, 2019.
Result Analysis: Sanofi rises in net profit, Sumeet Industries sees declines
Sanofi India posted results showing net profit and revenue growth YoY, but the company also showed a decline in operating profit margins, of 5.7% YoY. Potential impact on margins was likely from rupee depreciation, with Sanofi seeing recent quarter growth from export markets. Sanofi India imports specific products such as Lantus (insulin injections) from its group company, that it sells in Indian markets, while exports from Sanofi India have been targeted at semi-regulated developing countries. Textile company Sumeet Industries also posted quarterly results. The company's performance was disappointing, showing declines in YoY performance across the board, and a sharp fall in operating margins. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Dividend Updates
We refer to our letter dated 11th February 2019 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 12.00 noon and concluded at 04.30 p.m. The following items were considered and approved: Recommendation for payment of final dividend of Rs.66 per equity share of Rs. 10 each for the year ended 31st December 2018. Convening of the AGM of the Company on Tuesday, 7th May 2019. Closure of Register of Members and Share Transfer Books from 30th April 2019 to 7th May 2019 (both days inclusive) for determining the eligibility of shareholders for payment of final dividend and AGM. The final dividend, if approved by the shareholders shall be payable on or after 14th May 2019. Please take the above information on record. Sanofi India Ltd - 500674 - Results - Financial Results For 31St Dec 2018
We refer to our letter dated 11th February 2019 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 12.00 noon and concluded at 04.30 p.m. The Board approved audited financial results for the year ended 31st December 2018. We enclose a copy of the Auditor's Report and audited financial results of the Company for the year ended 31st December 2018 as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information. Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that the Statutory Auditors of the Company, M/s Price Waterhouse & Co. Chartered Accountants LLP have issued the Audit Report with unmodified opinion for the financial year ended 31st December 2018. Please take the above information on record. Sanofi India Ltd - 500674 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Sanofi India Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Sanofi India Ltd - 500674 - Clarification On The Media Report In 'The Hindu'
This has reference to your email dated 18th February 2019, with regard to the news item titled 'HC refuses to quash case against pharma firm' appearing in the Hindu at https://www.thehindu.com/news/national/karnataka/hc-refuses-to-quash-case-against-pharma-firm/article26285181.ece. We would like to inform you that the news report pertains to an order of the Honourable High Court of Karnataka which was pronounced on 15th February 2019. A copy of this order has not yet been made available to us as of 12.00 noon on 19th February 2019. The order pertains to a petition filed by the Company to quash on-going proceedings against the Company. In these proceedings, the trial court is yet to frame charges against the Company. The proceedings pertain to honorarium paid by the Company to a doctor in relation to patient education initiatives under valid contracts. We would also like to inform to you that this litigation is not a material event which requires reporting to the Stock Exchanges as per the Policy adopted by the Company for determination of materiality for disclosure of events or information to the Stock Exchanges pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015 and will not have a material impact on the Company.